Donanemab, a drug developed by Eli Lilly, has shown promise in slowing cognitive decline in Alzheimer’s disease. In a clinical trial, donanemab was shown to slow the decline in cognitive function by 25% over 18 months. This is the first drug to show such a significant benefit in slowing cognitive decline in Alzheimer’s disease.
Donanemab is a monoclonal antibody that targets amyloid plaques, which are thought to be a major cause of Alzheimer’s disease. Amyloid plaques are clumps of proteins that build up in the brains of people with Alzheimer’s disease. These plaques can damage neurons and lead to cognitive decline.
Donanemab works by binding to amyloid plaques and clearing them from the brain. This can help to slow the progression of Alzheimer’s disease and improve cognitive function.
The clinical trial of donanemab was conducted in people with early-stage Alzheimer’s disease. The participants were given either donanemab or a placebo. The results showed that the participants who received donanemab had a slower decline in cognitive function than the participants who received the placebo.
Donanemab is still in development, but it has the potential to be a major breakthrough in the treatment of Alzheimer’s disease. If approved by the FDA, donanemab could be the first drug to slow cognitive decline in Alzheimer’s disease.
Here are some of the key highlights about donanemab:
- It is a monoclonal antibody that targets amyloid plaques.
- It has shown promise in slowing cognitive decline in Alzheimer’s disease.
- It is still in development, but it has the potential to be a major breakthrough in the treatment of Alzheimer’s disease.
If you are concerned about Alzheimer’s disease, talk to your doctor about whether donanemab is right for you.
Fantastic Tech 